Log in

Relevant bibliographies by topics / Chronic myeloid leukaemia; Treatment

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Chronic myeloid leukaemia; Treatment'

Author: Grafiati

Published: 4 June 2021

Last updated: 4 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Chronic myeloid leukaemia; Treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Chronic myeloid leukaemia; Treatment"

1

Egyed, Miklós, Balázs Kollár, Péter Rajnics, Éva Karádi, and András Matolcsi. "Imatinib treatment of our chronic myeloid leukemia patients." Orvosi Hetilap 149, no. 32 (2008): 1509–12. http://dx.doi.org/10.1556/oh.2008.28354.

Full text

Abstract:

A krónikus myeloid leukaemia a pluripotens haemopoeticus őssejt malignus klonális betegsége. A kórkép genetikai háttere a t(9;22) (Philadelphia kromoszóma), amely konvencionális citogenetikával a krónikus myeloid leukaemiás esetek több mint 90%-ában kimutatható, illetve a bcr-abl fúziós gén, amely tirozin-kináz-aktivitású fúziós fehérje szintézisét kódolja. Mai ismereteink alapján ez a folyamatosan aktív tirozin-kináz a krónikus myeloid leukaemia oka. Az imatinib alkalmazása jelentősen megváltoztatta a krónikus myeloid leukaemia kezelését. Az eddigi eredmények a betegség minden fázisában magas

APA, Harvard, Vancouver, ISO, and other styles

2

Allan, Norman C., and Patricia C. A. Shepherd. "Treatment of chronic myeloid leukaemia." Baillière's Clinical Haematology 1, no. 4 (1987): 1031–54. http://dx.doi.org/10.1016/s0950-3536(87)80038-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ross, David M., Sharon R. Jackson, and Peter J. Browett. "Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia." Leukemia & Lymphoma 48, no. 6 (2007): 1231–33. http://dx.doi.org/10.1080/10428190701297360.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Onoja, AM, SA Otene, AT Onoja, et al. "Prevalence and Nature of Adult Hematological Malignancies Using Bone Marrow Aspiration Cytology in a Tertiary Health Facility: A Seven Year Retrospective Review." Western Journal of Medical and Biomedical Sciences 2, no. 1 (2021): 39–45. http://dx.doi.org/10.46912/wjmbs.39.

Full text

Abstract:

Bone Marrow Aspiration (BMA) is a procedure that is often used to evaluate patients with haematological disorders including haematological malignancies (HMs) which account for about 6.5% of all cancers worldwide. There is paucity of data on the prevalence and pattern of HMs from BMA cytology in Nigeria. We carried out a retrospective review to determine the prevalence and distribution of HMs among adult patients who had BMA cytology at Benue State University Teaching Hospital (BSUTH) from June 2012 to July 2019. A total of 158 BMA reports extracted from the marrow and clinic medical records we

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Interferon gamma treatment of chronic myeloid leukaemia." Inpharma Weekly &NA;, no. 719 (1990): 6. http://dx.doi.org/10.2165/00128413-199007190-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

O'Dwyer, Michael. "First-line treatment of chronic myeloid leukaemia." Therapeutic Advances in Hematology 1, no. 1 (2010): 15–22. http://dx.doi.org/10.1177/2040620710387981.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Howard, Joshua, Benedict Mackenzie, Toby Nicholson, Sylvia Connolly, and Rishee Parmar. "A unique presentation of destructive shoulder arthropathy in the chronic phase of chronic myeloid leukaemia." Shoulder & Elbow 11, no. 3 (2017): 210–14. http://dx.doi.org/10.1177/1758573217715260.

Full text

Abstract:

We present a previously unreported case of rapidly progressing, destructive shoulder arthropathy as an initial presentation of chronic phase chronic myeloid leukaemia. This patient initially presented to clinic for consideration of an arthroplasty for symptom relief; however, her loss to follow-up yielded a rapid progression of her symptoms. Bone marrow aspirate and targeted biopsy of the humeral head excluded blast cell crisis, in contrast to previously reported cases. She was treated conservatively with medical management of her underlying disease. Although leukaemic arthritis is a recognize

APA, Harvard, Vancouver, ISO, and other styles

8

Dokic, Marina, Ivana Urosevic, Ivanka Savic, et al. "A Case of Chronic Lymphocytic Leukaemia Occurring During Treatment of Chronic Myeloid Leukaemia." Indian Journal of Hematology and Blood Transfusion 32, S1 (2016): 156–58. http://dx.doi.org/10.1007/s12288-016-0638-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Jackson, Nicholas, Ahmad Shukri, and Kamaruzaman Ali. "Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy." British Journal of Haematology 85, no. 1 (1993): 203–4. http://dx.doi.org/10.1111/j.1365-2141.1993.tb08672.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Daniels, J. M. A., A. Vonk-Noordegraaf, J. J. W. M. Janssen, P. E. Postmus, and R. van Altena. "Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia." European Respiratory Journal 33, no. 3 (2009): 670–72. http://dx.doi.org/10.1183/09031936.00025408.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Chronic myeloid leukaemia; Treatment"

1

Chuah, Charles Thuan Heng. "Bisphosphonates in the treatment of Imatinib-resistant chronic myeloid leukaemia." Thesis, Imperial College London, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.429553.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Van, Rhee Frits. "Detection and treatment of residual disease in Philadelphia positive leukaemias." Thesis, Imperial College London, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.285168.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Deininger, Michael Werner Nikolaus. "STI571, a novel tyrosine kinase inhibitor : pre-clinical evaluation and application to identify downstream targets of BCR-ABL." Thesis, Imperial College London, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.325912.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Rusakiewicz, Sylvie. "Development of epitope-based immunotherapy for the treatment of chronic myeloid leukaemia." Thesis, University College London (University of London), 2005. http://discovery.ucl.ac.uk/1446802/.

Full text

Abstract:

Haematopoietic stem cell transplantation, one of the major treatments for Chronic Myeloid Leukaemia (CML), provides an allogeneic Graft-versus-Leukaemia (GvL) effect mediated by the donor T cells infused with the graft. The antigens recognized by these T cells are not yet identified. One candidate antigen is the CML specific BCR7ABL oncogene. The aim of this thesis is to investigate immunotherapeutic strategies for the treatment of CML targeted to BCR/ABL epitopes. We characterised BCR/ABL derived peptides that are naturally processed and presented on the surface of CML cells in the context of

APA, Harvard, Vancouver, ISO, and other styles

5

Mendes, Alexandrina Maria da Silva. "Evolution of treatment response to IMATINIB in patients diagnosed with chronic myeloid leukaemia." Dissertação, Instituto de Ciências Biomédicas Abel Salazar, 2008. http://hdl.handle.net/10216/20905.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mendes, Alexandrina Maria da Silva. "Evolution of treatment response to IMATINIB in patients diagnosed with chronic myeloid leukaemia." Master's thesis, Instituto de Ciências Biomédicas Abel Salazar, 2008. http://hdl.handle.net/10216/20905.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Cheng, Man-ying, and 鄭文瑛. "Prescribing pattern of imatinib among chronic phase chronic myeloid leukaemia (CML) patients and its financial impact on Hong Kong." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/196548.

Full text

Abstract:

Background: Chronic myeloid leukaemia (CML) is a haematological malignant disease involving haematopoietic stem cells. It is caused by a known reciprocal chromosomal t(9;22)(q34;q11) translocation, or known as Philadelphia chromosome. The translocation results in the formation of a chimeric BCR-ABL fusion gene. In the most recent guidelines published by NCCN and European LeukemiaNet in 2013, tyrosine kinase inhibitors (TKI) specifically inhibiting the Bcr-Abl tyrosine kinase, are the first-line therapy for patients with chronic phase CML. Imatinib is the oldest among the 3 TKI, and is the most

APA, Harvard, Vancouver, ISO, and other styles

8

Heaney, Nicholas Benjamin. "Proteasome inhibition in chronic myeloid leukaemia." Thesis, Connect to e-thesis, 2009. http://theses.gla.ac.uk/832/.

Full text

Abstract:

Thesis (MD.) - University of Glasgow, 2009.<br>MD. thesis submitted to the Faculty of Medicine, Division of Cancer Sciences and Molecular Pathology, University of Glasgow, 2009. Includes bibliographical references. Print version also available.

APA, Harvard, Vancouver, ISO, and other styles

9

Cwynarski, Katherine Louise. "Targets for therapy of chronic myeloid leukaemia." Thesis, Imperial College London, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.412517.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Abu-Eisha, Hazem Mahmoud. "T-cell responses in chronic myeloid leukaemia." Thesis, University of Liverpool, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.421045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Chronic myeloid leukaemia; Treatment"

1

Smithies, Alison. Alpha interferon in the treatment of chronic myeloid leukaemia. R&D Directorate, NHS Executive South and West, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. National Institute for Clinical Excellence, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. National Institute for Clinical Excellence, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Saglio, Giuseppe, and Carmen Fava. The Treatment of Chronic Myeloid Leukemia. Future Medicine Ltd, 2013. http://dx.doi.org/10.2217/9781780842738.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Brereton, Michelle Lorraine. In vitro growth characteristics of leukaemic and residual normal haemopoietic cells in chronic myeloid leukaemia. University of Salford, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Hancock, Sarah. Fludarabine as first line therapy for chronic lymphocytic leukaemia. University of Birmingham, Department of Public Health and Epidemiology, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Chapman, Rachel Susan. Investigation into the relationship between expression of the activated Abelson oncogene, drug sensitivity and suppression of apoptosis in chronic myeloid Leukaemia. University of Manchester, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

M, Carella Angelo, ed. Chronic myeloid leukaemia: Biology and treatment. Martin Dunitz, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Imatinib Mesylate In The Treatment Of Chronic Myeloid Leukaemia The Malaysian Experience. Lap Lambert Academic Publishing, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Bone and soft tissue malignancies. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689842.003.0025.

Full text

Abstract:

Haematological malignancies examines the epidemiology, genetics, clinical presentation and classification of these diseases, and presents current treatment approaches for each. First are the acute leukaemias, and the management of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Chronic myeloid leukaemia, its genetics and sensitivity to tyrosine kinase inhibitors, is described. Myelodysplastic syndromes and their management, are followed by chronic lymphoid leukaemias, a large heterogeneous group of diseases, and their treatment. Hodgkin lymphoma, its pathology and presen

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Chronic myeloid leukaemia; Treatment"

1

Goldman, John M., and Tariq I. Mughal. "Chronic Myeloid Leukaemia." In Postgraduate Haematology. Wiley-Blackwell, 2010. http://dx.doi.org/10.1002/9781444323160.ch27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Yeung, David TO, and Timothy P. Hughes. "Chronic Myeloid Leukaemia." In Postgraduate Haematology. John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118853771.ch24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mughal, Tariq I. "Chronic Myeloid Leukaemia." In Precision Haematological Cancer Medicine. CRC Press, 2018. http://dx.doi.org/10.1201/9781315380513-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Casolari, Debora A., and Junia V. Melo. "Chronic Myeloid Leukaemia." In Chromosomal Translocations and Genome Rearrangements in Cancer. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-19983-2_7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Krsnik, I., P. C. Srivastava, and D. A. G. Galton. "Chronic Myelomonocytic Leukaemia and Atypical Chronic Myeloid Leukaemia." In Myelodysplastic Syndromes. Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-75952-9_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Höglund, Martin, Fredrik Sandin, Bengt Simonsson, and Leif Stenke. "Epidemiology of Chronic Myeloid Leukaemia." In Hematologic Malignancies. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-71913-5_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Barnes, D. J., and J. V. Melo. "Molecular Basis of Chronic Myeloid Leukaemia." In Chronic Myeloproliferative Disorders. KARGER, 2002. http://dx.doi.org/10.1159/000068106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Abruzzese, Elisabetta, and Jane F. Apperley. "Managing Pregnancy in Chronic Myeloid Leukaemia." In Hematologic Malignancies. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-71913-5_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Shanmuganathan, Naranie, Bradley Chereda, and Junia V. Melo. "The Biology and Pathogenesis of Chronic Myeloid Leukaemia." In Hematologic Malignancies. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-71913-5_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Kaeda, J., A. Chase, and J. M. Goldman. "Cytogenetic and Molecular Monitoring of Residual Disease in Chronic Myeloid Leukaemia." In Chronic Myeloproliferative Disorders. KARGER, 2002. http://dx.doi.org/10.1159/000068096.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Chronic myeloid leukaemia; Treatment"

1

Woessner, David W., Andrew S. Dixon, and Carol S. Lim. "Abstract 1780: Potentiating chronic myeloid leukaemia treatment using oligomeric disruption and RNAi." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-1780.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Chang, H., and A. Astolfi. "Enhancement of the immune response to chronic myeloid leukaemia via controlled treatment scheduling." In 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2009. http://dx.doi.org/10.1109/iembs.2009.5332648.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Fahmy, S., A. M. El-Geziry, E. Mohamed, Amr M. AbdelAty, and A. G. Radwan. "Fractional-order mathematical model for Chronic Myeloid Leukaemia." In 2017 European Conference on Circuit Theory and Design (ECCTD). IEEE, 2017. http://dx.doi.org/10.1109/ecctd.2017.8093247.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Gil, S. García, GJ Nazco Casariego, MM Viña Romero, et al. "4CPS-117 Relationship between daily dose frequency and adherence in chronic myeloid leukaemia." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Alarcon-Payer, C., JM Puerta Puerta, A. Jiménez Morales, R. Claramunt García, and F. Horno Ureña. "4CPS-080 Real life tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukaemia." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.181.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Rovida, E., I. Tusa, G. Cheloni, et al. "PO-145 ERK5 pathway inhibitors inhibit the maintenance of chronic myeloid leukaemia stem cells." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.186.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Rocca, S., F. D’Anna, F. Fusella, et al. "PO-356 MicroRNA mediated regulation of morgana, a new oncosuppressor in chronic myeloid leukaemia." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.868.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Guindo, P. Nieto, H. Mateo Carrasco, FD Fernandez Gines, and E. Molina Cuadrado. "CP-137 Economic analysis of azacitidine versus decitabine for the treatment of acute myeloid leukaemia." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.136.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Garreta, G., A. Manzaneque, P. Velez, et al. "5PSQ-095 Analysis of the toxicities associated with tyrosine kinase inhibitors in patients with chronic myeloid leukaemia." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.412.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Fernandez Oliveira, C., E. Fernández Gabriel, M. Outeda Macías, MS Noya Pereira, and I. Martín Herranz. "4CPS-086 Imatinib dose optimisation through therapeutic monitoring in chronic myeloid leukaemia as part of pharmaceutical care." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.187.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Chronic myeloid leukaemia; Treatment"

1

Zhang, Dong-Er. Protein ISG15 Modification in the Development and the Treatment of Chronic Myeloid Leukemia. Defense Technical Information Center, 2007. http://dx.doi.org/10.21236/ada482354.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!